惠州市外地迁入居民与当地居民的儿童行为对照研究

惠州市外地迁入居民与当地居民的儿童行为对照研究俞世英禹顺英广东省惠州市人民医院儿科湖南医科大学精神卫生研究所Ａｃｈｅｎｂａｃｈ父母用儿童行为量表（ＣｈｉｌｄｂｅｈａｖｉｏｒＣｈｅｃｋｌｉｓｔ，ＣＢＣＬ）及在其基础上制定的Ａｃｈｅｎｂａｃｈ教师报告表（...     

海南特区中小学生行为问题因子结构分析

本文采用Ａｃｈｅｎｂａｃｈ’ｓ儿童行为量表 (ＣＢＣＬ)对海南特区的中小学生现状进行了调查研究 ,报告如下 :根据分层整群抽样的原则对海南省180 0名中小学生进行抽样调查 ,请小学生家长到校集中填写问卷 ;中学生以班为单位用指导语进行团体测试。得分按Ａｃｈｅｎｂａｃｈ’ｓ儿童行为量表 (ＣＢＣＬ)中国标准化版检核 ,获有效问卷 16 5 2份。运用ＳＰＳＳ8 0统计软件包在 5 86微机上处理。结果与讨论一、行为问题检出率海南省中小学生行为问题检出率为13 80 % (2 2 8/16 5 2 ) ,与全国的部分城市调查结果相近 ,两组资料间无统计学差异 …     

Achenbach儿童行为量表的湖南常模

在湖南省六个有代表性的地区城乡抽取４～１６岁正常儿童１２４８名，对Ａｃｈｅｎｂａｃｈ儿童行为量表（ＣｈｉｌｄＢｅｈａｖｉｏｕｒＣｈｅｃｋｌｉｓｔ，ＣＢＣＬ）进行标准化，制定了湖南常模。经信度、效度检验，认为６～１１、１２～１６岁男、女常模适用于我国儿童，而４～５岁男、女常模的信度、效度不够理想。     

电脑筛查儿童心理卫生问题

电脑筛查儿童心理卫生问题上海市精神卫生中心忻仁娥从美国引进的Ａｃｈｅｎｂａｃｈ′ｓ儿童行为量表（ＣＢＣＬ），在中国２２个城市中协作进行标准化研究后，制定了中国及２２个城市的常模，并被推广到儿保科，教育系统及心理界，作为儿童心理卫生问题筛查工具而被广泛...     

中学生自我概念与其行为问题的相关研究

目的：探讨中学生自我概念各因子与其行为问题的关系。方法：用Ｐｉｅｒｓ－Ｈａｒｒｉｓ儿童自我概念量表（ＰＨＣＳＳ）和Ａｃｈｅｎｂａｃｈ儿童行为量表（ＣＢＣＬ）测试中学生自我概念行为问题,并进行相关分析。结果：中学生自我概念各分量表上的得分与其社会能力呈显著正相关,与内向、外向行为问题及行为问题分基基本上呈显著负相关,而且不同自我概念组的中学生在行为问题量表上得分有显著差异。结论：自我概念水平不同及其     

CBCL及TRF在儿童精神障碍流行学调查中的应用—兼论划界分的选择

为检验Ａｃｈｅｎｂａｃｈ《儿童行为量表》（ＣＢＣＬ）及《老师报告表》（ＴＲＦ）用于儿童精神障碍流行学调查的真实性、可靠性，以ＤＳＭ－Ⅲ－Ｒ及临床诊断作金标准，分析两量表对湖南省儿童精神障碍流行学调查中发现的异常儿童诊断的灵敏度、特异度、诊断一致性。结果认为两量表可以用作流行学调查的筛查工具，其灵敏度ＣＢＣＬ大于ＴＲＦ，两量表相结合则更好；对破坏性行为障碍的灵敏度优于情绪障碍。使用ＲＯＣ分析制定了最佳划界标准     

单亲儿童行为调查

用Ａｃｈｅｎｂａｃｈ儿童行为量表，调查三所小学２６名单亲儿童作为实验组，随机选取一般家庭的儿童６０名作为对照组，结果显示，两组儿童在躯体不适、敌意、不成熟、强迫行为等方面有明显差异。     

香港和成都市儿童行为量表(CBCL)跨地区比较研究

目的：比较香港和成都市少年儿童的行为和情绪问题，探讨社会文化因素对评定结果的影响。方法：使用Ａｃｈｅｎｂａｃｈ儿童行为量表对香港２６７３名，成都市８５８名６－１８岁样本进行评定。结果：发现ＣＢＣＬ多数综合征评分香港地区高于成都。作用强度分析可见两地的焦虑抑郁，注意缺陷和外向性因子的差异特别明显。结论：可能香港少年儿童的心理问题出现率高于成都市，但也不能排除两地父母对儿童心理问题的认识理解、态度以及     

6—11岁儿童行为问题及其相关因素调查

６～１１岁儿童行为问题及其相关因素调查河南省焦作市妇幼保健院陶维娜徐相蕊李焕娣本文采用美国“Ａｃｈｅｎｂａｃｈ”儿童行为量表中国标准化版对焦作市６～１１岁儿童进行了行为调查，为我市儿童行为问题的防治工作提供依据。对象与方法采用整群、随机、分层相结合的...     

Achenbach儿童行为评定量表在7—11岁品行障碍儿童中的初步应用

Ａｃｈｅｎｂａｃｈ儿童行为评定量表在７～１１岁品行障碍儿童中的初步应用罗学荣，万国斌，杨志伟，苏林雁，李雪荣湖南医科大学精神卫生研究所品行障碍（Ｃｏｎｄｕｃｔｄｉｓｏｒｄｅｒ，ＣＤ）是儿童期常见的一种心理卫生问题，据调查７～１６岁儿童ＣＤ患病率为１．...     

The accuracy of MU calculations for dynamic wedge with the Varian's Anisotropic Analytical Algorithm

In November 2007 Varian Medical Systems released a new version of ECLIPSE (version 8.1.17), which includes a correction to its Anisotropic Analytical Algorithm affecting monitor unit calculations for Enhanced Dynamic Wedge. The purpose of this study is to evaluate and compare the accuracy of the MU calculations for version 8.1.17 with that from the previous version (8.0.05).     

Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay

We developed a new assay for human immunodeficiency virus type 2 plasma RNA quantification based on a previous format. The new version performed significantly better than the original regarding the detection of subtype B, allowing the detection of 14 out of 36 plasma RNAs in the subtype B-infected patients not detected with the original version.     

Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay

Hepatitis C virus (HCV) isolates have been classified into six main genotypes. Genotyping methods, and especially the widely used line probe assay (LiPA), are frequently based on the 5'-untranslated region (5'UTR). However, this region is not appropriate for discriminating HCV strains at the subtype level and for distinguishing many genotype 6 samples from genotype 1. We investigated the capacity of a novel LiPA (Versant HCV Genotype 2.0 assay) based on the simultaneous detection of 5'UTR and Core regions for genotypes 1 and 6 to provide correct HCV genotypes (characterized with a phylogenetic analysis) in a set of HCV strains mainly encountered in Western countries. The improvement was assessed by comparing the results to those obtained with the previous version of the assay. Of the 135 tested samples, 64.7% were concordant for genotype group and subtype with sequencing reference results using the Versant HCV Genotype 2.0 assay versus 37.5% with the previous version. The yield was mainly related to a better characterization of genotype 1, since the accuracy, tested in 62 genotype 1 samples, increased from 45.2% with the first version to 96.8% with the new one. However, this new version necessitates a specific PCR and could no longer be used after 5'UTR PCR used for current HCV infection diagnosis. Moreover, the information provided by 5'UTR hybridization is not reliable for correctly identifying the diversity within genotypes 2 and 4. Thus, the Versant HCV Genotype 2.0 assay remains a useful tool for clinical practice when only the discrimination between major HCV genotypes is necessary.     

Efficacy of a murine-p75-saporin immunotoxin for selective lesions of basal forebrain cholinergic neurons in mice

Selective lesioning of cholinergic neurons in the basal forebrain provides a tool for examining the functional significance of cholinergic loss, which is associated with a number of developmental and neurodegenerative disorders. A new version of an immunotoxin (murine-p75NTR-saporin) was used to produce a selective loss of cholinergic neurons in the adult basal forebrain of the mouse. This new version of the toxin is significantly more potent and selective than a previously developed version. C57Bl/6J mice (n = 30) were given 1 μL of either saline or murine-p75NTR-saporin (0.65 μg/μL or 1.3 μg/μL) into the lateral ventricles, and then sacrificed 10–12 days post-surgery for histological analysis. In contrast to results from the previous version of the toxin, survival of the toxin-treated mice was 100% at both doses. A complete loss of cholinergic neurons was seen in the medial septum (MS) with both doses, while a dose-dependent loss of cholinergic neurons was observed in the nucleus basalis magnocellularis (nBM). The lesions were associated with locomotor hypoactivity and anxiolytic-type behavioral effects. These studies describe the efficacy and selectivity of this new version of murine-p75NTR-saporin, which may be used to provide insight into functional deficits that result from the loss of cholinergic neurons in the mouse basal forebrain.     

Building a flexible protocol information system with ready for use' web-technology

This paper describes how web technology, currently available, can be used to build a fast and easy flexible protocol information system. The interface design and functionalities of the system were based on experiences with a previous version of a protocol information system (ProtoVIEW). A wide range of diagnostic or therapeutic protocols could be retrieved and viewed with ProtoVIEW. The Web-based version contains all functionalities of the non web-based version plus several new functionalities. The web version contains an X-ray viewer and a great deal of interactivity such as validation of electronic patient data forms. The most important additional function is the context sensitive protocol support that may lead to improved protocol adherence. Finally, the web-based version can be accessed from any working place since patient data and protocols are stored centrally.     

Performance of an automated system for quantification of hepatitis C virus RNA

The Amplicor HCV Monitor test for quantitative determination of serum or plasma hepatitis C virus (HCV) RNA was modified recently and introduced onto the Cobas Amplicor instrument to automate fully amplification, detection and calculation of results. This new version (v2.0) was evaluated in a routine diagnostic laboratory. The sensitivity and reproducibility were assessed on well-characterized panels (Eurohep) and clinical samples. HCV RNA levels measured by the v2.0 Monitor test were about 1log(10) higher than those detected by the previous version test, and genotypes 1 and 3 were quantified with equal sensitivity. Within the linear dynamic range of 10(3) to 10(6) copies/ml, the coefficients of variation for both intra- and inter-assay reproducibility ranged from 1.9 to 2.95%. This test system was found to be a reliable and labor saving assay for the quantification of HCV RNA.     

Multicenter evaluation of the updated and extended API (RAPID) Coryne database 2.0.

In a multicenter study, 407 strains of coryneform bacteria were tested with the updated and extended API (RAPID) Coryne system with database 2.0 (bioMérieux, La-Balme-les-Grottes, France) in order to evaluate the system's capability of identifying these bacteria. The design of the system was exactly the same as for the previous API (RAPID) Coryne strip with database 1.0, i.e., the 20 biochemical reactions covered were identical, but database 2.0 included both more taxa and additional differential tests. Three hundred ninety strains tested belonged to the 49 taxa covered by database 2.0, and 17 strains belonged to taxa not covered. Overall, the system correctly identified 90.5% of the strains belonging to taxa included, with additional tests needed for correct identification for 55.1% of all strains tested. Only 5.6% of all strains were not identified, and 3.8% were misidentified. Identification problems were observed in particular for Corynebacterium coyleae, Propionibacterium acnes, and Aureobacterium spp. The numerical profiles and corresponding identification results for the taxa not covered by the new database 2.0 were also given. In comparison to the results from published previous evaluations of the API (RAPID) Coryne database 1.0, more additional tests had to be performed with version 2.0 in order to completely identify the strains. This was the result of current changes in taxonomy and to provide for organisms described since the appearance of version 1.0. We conclude that the new API (RAPID) Coryne system 2.0 is a useful tool for identifying the diverse group of coryneform bacteria encountered in the routine clinical laboratory.     

Verification of a rounded leaf-end MLC model used in a radiotherapy treatment planning system

A new multileaf collimator (MLC) model has been incorporated into version 7.4 of the Pinnacle radiotherapy treatment planning system (Philips Radiation Oncology Systems, Milpitas, CA). The MLC model allows for rounded MLC leaf-ends and provides separate parameters for inter-leaf transmission, intra-leaf transmission and the tongue width of the MLC leaf. In this report we detail the method followed to commission the MLC model for a Varian 120-leaf Millennium MLC (Varian Medical Systems, Palo Alto, CA, USA) for both 6 and 10 MV photons, and test the validity of the model for an IMRT field. Dose profiles in water were measured for a range of square MLC field sizes and compared to the Pinnacle computed dose profiles; in addition, the dose distribution for a series of adjacent MLC fields was measured to observe the model's behaviour along match-lines. Based on these results intra-leaf transmissions of 1.5% for 6 MV and 1.8% for 10 MV, leaf-tip radius of 12.0 cm, an inter-leaf transmission of 0.5%, and a tongue width of 0.1 cm were chosen. Using these values to compute the planar dose distribution for a 6 MV IMRT field, the new version of Pinnacle displayed improved dosimetric agreement with the dose-to-water EPID image and ion chamber measurements when compared to the old version of Pinnacle, particularly along the MLC tongue edge and across match-lines. Discrepancies of up to 5% were observed between calculated and measured doses along match-lines for both 6 MV and 10 MV photons; however, the new MLC model did predict the presence of match-lines and was a significant improvement on the previous model.     

Comprehensive Application of the International Classification of Headache Disorders Third Edition,Beta Version

The purpose of this study was to test the feasibility and usefulness of the International Classification of Headache Disorders, third edition, beta version (ICHD-3β), and compare the differences with the International Classification of Headache Disorders, second edition (ICHD-2). Consecutive first-visit patients were recruited from 11 headache clinics in Korea. Headache classification was performed in accordance with ICHD-3β. The characteristics of headaches were analyzed and the feasibility and usefulness of this version was assessed by the proportion of unclassified headache disorders compared with ICHD-2. A total of 1,627 patients were enrolled (mean age, 47.4±14.7 yr; 62.8% female). Classification by ICHD-3β was achieved in 97.8% of headache patients, whereas 90.0% could be classified by ICHD-2. Primary headaches (n=1,429, 87.8%) were classified as follows: 697 migraines, 445 tension-type headaches, 22 cluster headaches, and 265 other primary headache disorders. Secondary headache or painful cranial neuropathies/other facial pains were diagnosed in 163 patients (10.0%). Only 2.2% were not classified by ICHD-3β. The main reasons for missing classifications were insufficient information (1.6%) or absence of suitable classification (0.6%). The diagnoses differed from those using ICHD-2 in 243 patients (14.9%). Among them, 165 patients were newly classified from unclassified with ICHD-2 because of the relaxation of the previous strict criteria or the introduction of a new diagnostic category. ICHD-3β would yield a higher classification rate than its previous version, ICHD-2. ICHD-3β is applicable in clinical practice for first-visit headache patients of a referral hospital.     

Assessment of motivational interviewing with the VASE-(Mental) Healthcare: Mixed-methods study to examine feasibility and validity in the general practice setting

ObjectiveThe VASE-(M)HC is an instrument to evaluate Motivational Interviewing (MI) skills. We adjusted the previous version for use in the broader (mental) healthcare context, incorporated new MI insights, expanded the scoring system and created a parallel version. Feasibility and validity evidence in the general practice setting was explored.MethodsThe teaching staff of the GP specialty-training, GP-, and PN-trainees (N = 156) completed the VASE-(M)HC. In this mixed-methods study, we examined psychometric characteristics, compared parallel versions, and interviewed assessors.ResultsOur adjustments enable assessment of a wider range of MI skills, and allow differentiation of basic and advanced skills. Inter-rater reliability was excellent and internal consistency of the total scale was good for both versions. The parallel versions are comparable in terms of difficulty.ConclusionThe VASE-(M)HC is improved by our revisions and adds multiple advantages to the domain of available MI assessment tools.Practice implicationsDue to the adjustments, the instrument can be used in the GP setting (instead of sole focus on substance abuse). The parallel version is useful for research (pretest/posttest) and selective assessment (retake of a test). It is promising to further explore its applicability in the broader (mental) healthcare context and as training material.